Navigation Links
Results of the ARCTIC-INTERRUPTION trial presented at TCT 2013
Date:10/31/2013

SAN FRANCISCO, CA October 31, 2013 According to a new study, patients that do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual antiplatelet therapy (DAPT). Results from the ARCTIC-INTERRUPTION trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The optimal length of time for DAPT after coronary stenting remains uncertain with an unknown safety to efficacy ratio of prolonged therapy. Currently there are discrepancies between international guidelines and high variability in routine practice. The ARCTIC-INTERRUPTION study was a prospective randomized trial that examined the benefit of the continuation of DAPT for up to two years.

ARCTIC-INTERRUPTION randomly assigned 1,259 patients without major events within the first year after coronary stenting to either a strategy of interruption of DAPT (n=624), or a strategy of continuation for an additional year (n=635). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization after one year.

The primary endpoint occurred in 3.8 percent of patients in the continuation group, as compared to 4.3 percent in the interruption group. The main secondary endpoint of stent thrombosis or any urgent revascularization occurred in 1.3 percent of patients in the continuation group and 1.6 percent of those in the interruption group. The rate of major bleeding events occurred in 1.1 percent of the patients in the continuation group compared to 0.2 percent in the interruption group.

"The ARCTIC-INTERRUPTION study suggests no ischemic benefit of DAPT continuation beyond one year after stenting in patients that do not experience an adverse event within the first year," said lead investigator Gilles Montalescot, MD, PhD. Dr. Montalescot is Professor of Cardiology at Centre Hospitalier Universitaire Piti-Salptrire in Paris, France.

"Further, the study found significantly more major and minor bleeding events with DAPT continuation."


'/>"/>

Contact: Judy Romero
jromero@crg.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013
2. HIPAA Crackdown Results in Expansion of Secure Texting Solution for Physicians
3. Results of the COREVALVE EXTREME RISK trial presented at TCT 2013
4. Results of the SAFE-PCI trial presented at TCT 2013
5. Aggressive treatment of psoriatic arthritis results in significant improvement, says new research
6. National Resident Matching Program® (NRMP®) Publishes Results of the 2013 Applicant Survey by Preferred Specialty and Applicant Type
7. Visage Sculpture, Premiere Cosmetic Clinic of Boston, Reports Shorter-lasting Results of Fillers in Athletes and Offers a Solution
8. Kimono Condoms are the Thinnest. New Testing Results Confirm
9. IBTA Announces PF23 Results and First-Ever EDR Compliance Testing
10. Diet Doc Hormone Diets & Weight Loss Plans Announces New Medically Guided Diet Plans Designed to Naturally Increase Healthy Hormone Function While Also Producing Results
11. Diet Doc Weight Loss Plans Reveals New Diet Plans and Fat Burning Foods that Help Patients Achieve Snookie Type Weight Loss Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: